# Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut

Source: https://onco.cc/trials/nct07805954/  
OnCo record `nct07805954` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Daraxonrasib, Gemcitabine, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Revolution Medicines, Inc., now recruiting.

## Summary

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma is a phase 3 interventional study registered as NCT07805954 by Revolution Medicines, Inc., with 400 participants planned, started 2026-08-28 and due to reach its primary completion in 2029-03. Interventions recorded: daraxonrasib, gemcitabine, nab-paclitaxel, zoldonrasib. Conditions listed: Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Also known as: RASolute 309
- Tags: ctgov-ingest
- Registry id: NCT07805954
- Phase: 3
- Setting: A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
- Sponsor: Revolution Medicines, Inc.
- Enrolled: 400

## Notes

- RASolute 309 (registry, 24 September 2026): phase 3, open-label, zoldonrasib plus daraxonrasib against gemcitabine and nab-paclitaxel as first-line treatment for metastatic KRAS G12D-mutated pancreatic adenocarcinoma; 400 participants (estimated), recruiting, started 28 August 2026, primary completion March 2029; United States sites only so far.

## Sources

- ClinicalTrials.gov NCT07805954: https://clinicaltrials.gov/study/NCT07805954

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- drugs: [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Zoldonrasib](https://onco.cc/drugs/zoldonrasib/)
- companies: [Revolution Medicines](https://onco.cc/companies/revolution-medicines/)
- terms: [KRAS mutation subtypes (G12C, G12D, G12V)](https://onco.cc/terms/kras-mutation-subtypes/), [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)
- ideas: [RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression](https://onco.cc/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/)

---
JSON: https://onco.cc/api/v1/entities/nct07805954.json